 For the secondary objectives of noninferiority of the response to PsA-TT-5μg given with PRV and superiority of a supplemental dose of PRV, PsA-TT-5μg immunogenicity will be evaluated by measuring the serum bactericidal activity SBA seroconversion rates and GMTs 4 weeks post-vaccination. PRV immunogenicity will be evaluated by measuring the anti-rotavirus Immunoglobulin A IgA and immunoglobulin G IgG seroconversion rates and GMCs 4 weeks post-vaccination. 